Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-12-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell transplantation, in patients with type 1 diabetes mellitus who have a stable kidney allograft.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

NCT00888628

Diabetes Mellitus, Type I

COMPLETED PHASE1/PHASE2

Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants

NCT00288977

Diabetes Kidney Transplantation

COMPLETED NA

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

NCT01123187

Immunosuppression Type 1 Diabetes Organ Transplantation

COMPLETED NA

Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease

NCT00692562

Type 1 Diabetes Mellitus End-stage Renal Disease

COMPLETED PHASE1/PHASE2

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

NCT03047200

Islet Cell Transplantation Type 1 Diabetes

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To reverse hyperglycemia and insulin dependency by islet cell transplantation, in patients with Type 1 Diabetes Mellitus who have a stable kidney allograft;
2. To eliminate the incidence of hypoglycemic coma and unawareness by islet cell transplantation;
3. To assess long-term function of successful islet cell transplants;
4. To determine whether the natural history of the microvascular, macrovascular and neuropathic complications of Diabetes Mellitus are altered following successful transplantation of islet cells.
5. To assess the effect of exenatide to improve islet graft function and survival in subjects that demonstrate partial graft loss and have returned to using exogenous insulin.
6. To assess the ability of exenatide to improve islet survival at time of islet transplantation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Islet Transplantation

Islet Transplantation in subjects with a previous kidney transplant.

Group Type EXPERIMENTAL

Islet Transplantation

Intervention Type DRUG

Islet Transplantation in subjects with a previous kidney transplant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Islet Transplantation

Islet Transplantation in subjects with a previous kidney transplant.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

islet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients between 18 and 60 years of age.
2. Patients with type 1 diabetes mellitus.
3. Patients with a renal transplant that is more than 6 months old.
4. Patients with stable renal graft function for the preceding 6 months, i.e. no episodes of rejection and changes in serum creatinine no more than 0.5 mg/dl from baseline.
5. Patients who are taking tacrolimus, sirolimus +/- steroids for maintenance immunosuppression for at least 6 months and are tolerating levels satisfactory for islet transplantation without severe complications.
6. Patients with a body mass index (BMI) of less than or equal to 26.

Exclusion Criteria

1. Stimulated or basal C-peptide \> 0.3 ng/ml.
2. Patients with unstable renal function - serum creatinine greater than 0.5 mg/dl above baseline.
3. Patients with proteinuria (albuminuria \> 300 mg in 24 hours +/- protein) of new onset since kidney transplantation. If proteinuria or albuminuria is thought to originate from the native kidney(s) this will not be an exclusion criterion.
4. Patients with corrected creatinine clearance of less than 40.
5. Patients weighing more than 80 kg.
6. Patients with a body mass index (BMI) of greater than 26.
7. Insulin requirement \> 1.0 U/kg/d.
8. Anemia (hemoglobin: males \< 11.0 g/dl; females \< 10.0 g/dl).
9. Abnormal liver function tests (consistently \> 1.5 x normal range).
10. Unstable diabetic retinopathy.
11. Evidence of acute or chronic active Epstein-Barr virus (EBV) infection (IgM ≥ IgG). Patients will be eligible if serological testing becomes consistent with previous exposure (i.e. IgG \> IgM).
12. Patients with history of malignancy or current malignancy other than non-melanomatous skin cancer, or finding of any lesions or symptoms during screening that are suspicious for malignancy, until properly investigated and ruled out.
13. Patients with elevation of prostate-specific antigen \> 4 unless malignancy has been excluded.
14. Patients with unstable cardiovascular status.
15. Patients with active infections until adequately treated, unless treatment is not judged as necessary by the investigators (including, but not limited to, mild skin and nail fungal infections).
16. Patients with serological evidence of infection with HIV, human t cell lymphotropic virus 1 (HTLV 1), HTLV 2, or hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable).
17. Patients with history and/or serological evidence of hepatitis C (those patients with hepatitis C, already transplanted in this protocol will continue in this trial).
18. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided).
19. Patients with active peptic ulcer disease, gallstones, hepatic hemangioma, or portal hypertension.
20. Patients who are pregnant or breastfeeding, or who intend to procreate.
21. Patients who are sexually active females who are not:

* post-menopausal,
* surgically sterile, or
* using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices combined with spermicidal gel are acceptable; condoms used alone are not acceptable).
22. Active alcohol or substance abuse; smoking in the last 6 months.
23. Patients with evidence of sensitization, i.e. panel reactive antibody (PRA) testing greater than 20%.
24. Lack of updated immunizations per current Centers for Disease Control (CDC) guidelines, as well as immunization against hepatitis B, pneumococcus, and influenza (during season), unless medically contraindicated.
25. Patients with psychogenic factors, which are judged at psychological evaluation, which make it unsafe to undergo islet transplantation, or which preclude therapeutic compliance.
26. Patients with any condition or any circumstance that would make it unsafe to undergo an islet transplant.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No